Literature DB >> 1666303

Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation.

P H Quax1, N Pedersen, M T Masucci, E J Weening-Verhoeff, K Danø, J H Verheijen, F Blasi.   

Abstract

The respective roles of urokinase plasminogen activator (u-PA) and the u-PA receptor in extracellular matrix degradation was investigated. Human pro-u-PA and the human u-PA receptor were expressed independently by two different mouse LB6 cell lines. The matrix degradation capacity of these cell lines individually or in coculture was studied. Although pro-u-PA-producing cells alone degrade the matrix in the presence of plasminogen, u-PA-receptor producing cells do not. Cocultivation of a small fraction of pro-u-PA-producing cells with the receptor-producing cells increases the rate of matrix degradation at least threefold. By immunoprecipitation it was shown that cocultivation of the two cell lines increases the conversion of the inactive pro-u-PA to the active two chain u-PA. The enhancement of matrix degradation and of pro-u-PA activation requires actual binding of pro-u-PA to its receptor because it is inhibited by u-PA-receptor antagonists. The u-PA receptor must be cell associated, as binding of pro-u-PA to a receptor solubilized from the cell surface with phosphatidyl-inositol specific phospholipase C did not enhance the activation of pro-u-PA in the presence of plasminogen. The finding that activity of u-PA is enhanced when it is bound to its receptor, even when the receptor is produced by a different cell, might have important implications for the mechanisms of u-PA-induced extracellular proteolysis in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1666303      PMCID: PMC361875          DOI: 10.1091/mbc.2.10.793

Source DB:  PubMed          Journal:  Cell Regul        ISSN: 1044-2030


  44 in total

1.  Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes.

Authors:  M P Stoppelli; A Corti; A Soffientini; G Cassani; F Blasi; R K Assoian
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

2.  Autocrine saturation of pro-urokinase receptors on human A431 cells.

Authors:  M P Stoppelli; C Tacchetti; M V Cubellis; A Corti; V J Hearing; G Cassani; E Appella; F Blasi
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

Review 3.  Plasminogen activators, tissue degradation, and cancer.

Authors:  K Danø; P A Andreasen; J Grøndahl-Hansen; P Kristensen; L S Nielsen; L Skriver
Journal:  Adv Cancer Res       Date:  1985       Impact factor: 6.242

4.  Destruction of extracellular matrices containing glycoproteins, elastin, and collagen by metastatic human tumor cells.

Authors:  P A Jones; Y A DeClerck
Journal:  Cancer Res       Date:  1980-09       Impact factor: 12.701

5.  Antibodies to plasminogen activator inhibit human tumor metastasis.

Authors:  L Ossowski; E Reich
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

6.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

7.  Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells.

Authors:  R Reich; E W Thompson; Y Iwamoto; G R Martin; J R Deason; G C Fuller; R Miskin
Journal:  Cancer Res       Date:  1988-06-15       Impact factor: 12.701

8.  Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody.

Authors:  L S Nielsen; J G Hansen; L Skriver; E L Wilson; K Kaltoft; J Zeuthen; K Danø
Journal:  Biochemistry       Date:  1982-12-07       Impact factor: 3.162

9.  A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.

Authors:  J D Vassalli; D Baccino; D Belin
Journal:  J Cell Biol       Date:  1985-01       Impact factor: 10.539

10.  A study of proteases and protease-inhibitor complexes in biological fluids.

Authors:  A Granelli-Piperno; E Reich
Journal:  J Exp Med       Date:  1978-07-01       Impact factor: 14.307

View more
  19 in total

Review 1.  Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors.

Authors:  H Malonne; I Langer; R Kiss; G Atassi
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

2.  Evidence that the inhibition of cartilage proteoglycan breakdown by mannosamine is not mediated via inhibition of glycosylphosphatidylinositol anchor formation.

Authors:  H Bryson; D J Buttle; L D Kozaci; R N Johnatty; R A Bunning
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

3.  Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices.

Authors:  M E Kroon; P Koolwijk; H van Goor; U H Weidle; A Collen; G van der Pluijm; V W van Hinsbergh
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

4.  Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.

Authors:  C Holst-Hansen; B Johannessen; G Høyer-Hansen; J Rømer; V Ellis; N Brünner
Journal:  Clin Exp Metastasis       Date:  1996-05       Impact factor: 5.150

5.  Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.

Authors:  T J de Vries; P H Quax; M Denijn; K N Verrijp; J H Verheijen; H W Verspaget; U H Weidle; D J Ruiter; G N van Muijen
Journal:  Am J Pathol       Date:  1994-01       Impact factor: 4.307

6.  Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis.

Authors:  Kyung Hee Lee; Myung Soo Hyun; Jae-Ryong Kim
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

7.  Sites of urokinase-type plasminogen activator expression and distribution of its receptor in the normal human kidney.

Authors:  S N Wagner; M J Atkinson; C Wagner; H Höfler; M Schmitt; O Wilhelm
Journal:  Histochem Cell Biol       Date:  1996-01       Impact factor: 4.304

8.  A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.

Authors:  N Pedersen; M Schmitt; E Rønne; M I Nicoletti; G Høyer-Hansen; M Conese; R Giavazzi; K Dano; W Kuhn; F Jänicke
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

9.  The effect of suramin on the resorption of bovine nasal cartilage.

Authors:  C L Lewis; A Frazer; R G Russell; R A Bunning
Journal:  Inflammopharmacology       Date:  1999       Impact factor: 4.473

10.  Increase of a urokinase receptor-related low-molecular-weight molecule in colorectal adenocarcinomas.

Authors:  H K Lau; M Kim; J Koo; B Chiu; D Murray
Journal:  Clin Exp Metastasis       Date:  1995-11       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.